Sign in
4

Changes in Ownership

LENZ Therapeutics, Inc. Filed Acc 0000899243-21-027016

CHIEF BUSINESS OFFICER acquired 94,789 shares (option exercise)

  • CHIEF BUSINESS OFFICER acquired 8,126 shares (conversion)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Gutry Phil CHIEF BUSINESS OFFICER 2021-01-15 Option exercise +91,406 $0.30 $27,422 281,962 D
Gutry Phil CHIEF BUSINESS OFFICER 2021-04-18 Option exercise +3,383 $6.11 $20,670 285,345 D
Gutry Phil CHIEF BUSINESS OFFICER 2021-06-29 Conversion +8,126 293,471 D
Derivatives
Gutry Phil CHIEF BUSINESS OFFICER 2021-01-13 Grant or award · Stock Option (right to buy) +91,406 91,406 D
Gutry Phil CHIEF BUSINESS OFFICER 2021-01-15 Option exercise · Stock Option (right to buy) −91,406 0 D
Gutry Phil CHIEF BUSINESS OFFICER 2021-03-11 Grant or award · Series B Preferred Stock +19,763 $5.06 $100,001 19,763 D
Gutry Phil CHIEF BUSINESS OFFICER 2021-03-17 Grant or award · Stock Option (right to buy) +162,410 162,410 D
Gutry Phil CHIEF BUSINESS OFFICER 2021-03-17 Grant or award · Stock Option (right to buy) +69,604 69,604 D
Gutry Phil CHIEF BUSINESS OFFICER 2021-04-18 Option exercise · Stock Option (right to buy) −3,383 159,027 D
Gutry Phil CHIEF BUSINESS OFFICER 2021-06-29 Conversion · Series B Preferred Stock −19,763 0 D
Loading xslF345X03/doc4.xml…